The U.S. Centers for Disease Control and Prevention (CDC, for its acronym in English) reported this Tuesday, October 19, the vaccine Pfizer / BioNTech tIt is 93% effective in the prevention of hospitalization in people aged 12 to 18 years.
The study was conducted between June 1 and September 30 when there was a record that the Delta variant coronavirus, which included 19 pediatric hospitals in 16 states.
What was evaluated was the efficacy of 2 doses of the vaccine against hospitalization for Covid-19 in children and adolescents between 12 and 18 years. The sample consisted of β464 hospitalized persons aged 12 to 18 years (179 case-patients and 285 controls), the median age was 15 years, 72% had at least one underlying condition, including obesity, and 68% attended face-to-face school β.
βIn this real-world analysis, in which all the patients were hospitalized, Vaccination reduced the risk of hospitalization for COVID-19 in people ages 12 to 18 by 93%. Additionally, 16% of hospitalized COVID-19 patients had a critical illness requiring life support; all were not vaccinated β, it is indicated.
In addition, it is indicated that until October 18, 2021, 46% of American children and adolescents aged 12 to 15 years were vaccinated and 54% of 16 to 17 years had been administered the biological.
The drug is authorized by the Food and Drug Administration (FDA) for use in people under 18 years of age and up to 12 years of age.
It should be noted that it is intended that the biological is authorized in children of 5 years or more.
A group of FDA experts is expected to evaluate the data regarding minors later this month.
KEEP READING:
Johnson & Johnson Asks FDA To Apply Booster Dose Of Its COVID-19 Vaccine
European Agency authorizes the application of a third dose of Pfizer in people over 18 years of age
